Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are drugs containing the active ingredient bexarotene. The subject of the agreement are drugs containing the active ingredient buserelin in the implant dosage form. The subject of the Agreement are drugs containing the active ingredient caspofungin. The Contractual Products are medicinal products containing the active ingredient cefadroxil in the dosage form tablet. The subject of the agreement are medicinal products containing the active ingredient dasatinib. The subject of the agreement are drugs containing the active ingredient dasatinib in an off-patent indication. The subject of the agreement are medicinal products containing the active substance dexamethasone in the dosage form ampoule. The subject of the Agreement are medicinal products containing the active substance fluorouracil in the pharmaceutical form of cream. The subject of the Agreement are medicinal products containing the active ingredient combination fluticasone furoate and vilanterol. The subject of the Agreement are medicinal products containing the active ingredient iloprost. The subject of the Agreement are medicinal products containing the active ingredient melatonin in a prescription-only, oral, sustained-release dosage form. The subject of the Agreement are medicinal products containing the active ingredient mepolizumab in an active strength of 100 mg and in the dosage form ready-to-fill syringe. The Contractual Products are medicinal products containing the active substance nilotinib. The Contractual Products are medicinal products containing the active substance peginterferon beta-1a. The subject of the agreement are medicinal products containing the active ingredient combination piribedil. The contract covers medicinal products containing the active ingredient rilpivirine in the form of film-coated tablets. The contract covers medicinal products containing the active ingredient salmeterol in the dosage form of metered-dose inhalers. The subject of the Agreement are drugs containing the active ingredient sirolimus. The contract relates to drugs containing the active ingredient tafamidis. The contract covers drugs containing the active ingredient combination tafluprost and timolol. The contract covers drugs containing the active ingredient teriflunomide. The contract covers drugs that contain the active ingredient teriparatide (Forsteo®) or are interchangeable with it according to the rules of substitution. The criteria for substitution are defined in the framework agreement on drug supply pursuant to Section 129 (2) of the German Social Code, Book V, as amended. The contract covers drugs that contain the active ingredient teriparatide (Livogiva®) or are interchangeable with it according to the rules of substitution. The criteria for substitution are defined in the framework agreement on the supply of medicines pursuant to Section 129 (2) of the German Social Code, Book V, as amended from time to time. The contract covers drugs that contain the active ingredient teriparatide (Movymia®_Terrosa®) or are interchangeable with it according to the rules of substitution. The criteria for substitution are defined in the framework agreement on the supply of medicines pursuant to Section 129 (2) of the German Social Code, Book V, as amended from time to time.

Opportunity closing date

01 August 2025

Value of contract

£0-100k